Mergers & AcquisitionsBy The Online Investor Staff, updated Fri., Feb. 3, 10:49 AM
|This Slide: #32 of 100|
Slide #32. Biosynex SA — Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc. (NASDAQ:CEMI)
Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, and Chembio Diagnostics, Inc. ("Chembio") (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the companies have entered into a definitive merger agreement under which Biosynex, through a subsidiary, will acquire Chembio for $0.45 per share, representing a premium of 27% compared to the closing price of Chembio stock on January 30, 2023, in an all-cash transaction valued at $17.2 million.
Free CEMI Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Hold (2.00 out of 4)